Member Info for Cliostock

Totally agree Aquae, I’m hoping for a mention on all those points. My calculations on revenue since year end are similar to yours, and hopefully the market is expecting similar.

I see this release as a real opportunity for SA to action his promises about better RNS communication he made after the revenue/distribution deal debacle. The less gaps he leaves the less space he leaves for the markets imagination to run wild. He needs to regain his lost position as the solid and reliable CEO we know he is.

Cheers for keeping track of this and posting the updated list Aquae.

As an ex-subscriber myself I also got the email, I thought it was a really good idea. Using email addresses of people that already know what the product is about is a really cheap way of taking advantage of Black Friday. I also think the buy 2 get 1 free is clever, as it will leave people with 3 months supply, which is long enough to get the product working for them in most cases.

Yes Bel an update should be included with the end of year results which should land within two weeks. Hopefully the post year end points will be acceptable.

Did either of you gentlemen attend the Manchester shareholders meeting?

Toyin, everyone understands the distribution deals. If you are trying the make the point that retail sales are going as the company hoped, I think the issue is we have a different tolerance to accept the realism of the situation. However I am invested here too, I like the company, I think it’s potential is phenomenal, and it nonsensical for me to try to fight the corner I’m currently standing in. I don’t want to be stood here. And I thoroughly hope in a couple of weeks the full year RNS reads that the sales have reached a level the company is happy with.

I don’t mean to put a downer on things Toyin, it’s just that our small team are obviously struggling with sales for it’s intended purpose, I don’t feel they can take on any more on top of this and the other pillars. Of course, if Elric struts into the next AGM looking like a Bee Gee then maybe we should drop the Psoriasis and focus on your findings!

I’m not generally one to judge or laugh at supposed discoveries like this, because the fact is, nobody knows, man nor beast. Its just a shame we’re not having such conversations about breakthroughs resulting in us selling our Psoriasis product, particularly to people that have Psoriasis.

Just to clarify, does everyone know that if you shave a dog, it’s coat will grow back with or without AxisBiotix, right? :-p

TW has today announced that he had an email exchange with SA earlier and all is going well with Croda, he has a meeting with them early December and there will be an RNS after that.

So what are we looking at from here?

I know I’m hoping for the full year results to be announced EOM showing small but reasonable growth in Axis sales, we know better than to expect miracles there, but 25k a month plus would be ok. And then confirmed revenue from Croda at any level to show there is truly no delays, and I think we could possibly be in the 40’s by Xmas. I know predictions are dangerous, but I do feel I know the company well enough to make one and my expectations are within reason. I should probably keep them to myself but I’m hoping it creates some discussion between those who agree and those with differing opinions.

Stuart has been clear that SOH communicates well with him, giving him advanced notice of intention to sell. Elric certainly made it known to Stuart in their last interview that investors are worried about OPTI moving stock, would this not make SA’s awareness of OPTI selling price sensitive and RNSable? We know how furious Stuart would be if SOH sold behind his back.

Genuine question, would OPTI really be moving stock in 5k and 10k tranches? Apart from one or two 100k sells, most of what we have seen in the last couple of weeks have been 5 and 10 k at a time.

From last trading update;

· Croda/Sederma

Further to previous announcements, the Company continues to engage with Croda and its active ingredient arm, Sederma, and awaits the outcome of its marketing activities to its 12,000 VIP global cosmetics clients, expected in Q4 2022.

Last year, the company released full year results on 30th November, so around then there is likely to be an RNS with some ‘post year end’ points, and there is potential for the beauty parade to be mentioned then. There is a strong chance that it will simply say it is on track, and if that is the case I would be expecting an independent RNS before Christmas informing us about it.

He is seen as a credible CEO??? I jest, of course. He certainly has some business acumen. But as an unbiased observer (never had any interest in OPTI) I can see his core business is just treading water and it’s not good enough, but he doesn’t seem to see it. Selling any SBTX at this level would speak volumes, because he’s almost guaranteed to get a better return on capital leaving it where it is than trying to expand his OPTI treadmill.

Unless he knows more than we do, which SA vehemently denies, he’d be mad to sell any decent holding at this price.

Yes I found that unusual today Oleric. I’m sure one of the guys with technical knowledge of the markets will be able to explain.

Am I right in remembering that the enhancement found many months ago when scaling up was to do with our technology improving the effectiveness of other ingredients? Please correct me if I am wrong, but at the moment do not have time to revisit all the podcasts and suchlike where this was discussed.

The reason for me mentioning it is having noticed what looks like a fairly recent product launch, ReVitAlide, where the product sales information seems to ring a bell with me against the enhancement claims:

“Dubbed ReVitAlide, the new ingredient is a lipid submicron particle carrying 3% active retinol. According to the Croda Personal Care subsidiary, this high-tech capsule provides enhanced stability, protecting retinol from degradation and making it easy to store and formulate.

“The small particle size and unique lipid composition of the capsule greatly improves bioavailability into the skin, with a controlled release process of the encapsulated retinol,” said Sederma in a statement.

Skin delivery of ReVitAlide measured on skin explants showed a 7-fold increase in the delivery of retinol into the skin versus non encapsulated retinol.”

What do we think?

Mol

What is your point?

SA has told us we should expect to see marketing material from Croda/Sederma towards the end of the summer, so it’s either out there already or it’s behind schedule, and we’ve been told it’s on schedule. I am not however trying to make the point that BB-Biont is part of the launch of skinbiotix, it is my own belief that it is not. I have not scoured patents like Aquae but I have attempted to carefully compare language and terms put out by Cath and the team whilst explaining the science during the creation, testing and commercialisation of Skinbiotix and the material currently out there about BB Biont, and there are hardly any similar terms used at all. This is not a foolproof but of research from myself, but I had hoped to see much more correlation if the product was Skinbiotix based.

Mol, your last couple of posts tell me you are far from being of the same mind as Aquae lol

Some good points raised last night and this morning - I don’t think we’ll get true clarification until we know if ‘BBB’ is us. I think there is a chance this may not be formally announced at all, and we may just get revenue numbers when they begin.